A detailed history of Franklin Street Advisors Inc transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Franklin Street Advisors Inc holds 11,400 shares of PTGX stock, worth $529,644. This represents 0.03% of its overall portfolio holdings.

Number of Shares
11,400
Previous 11,470 0.61%
Holding current value
$529,644
Previous $397,000 29.22%
% of portfolio
0.03%
Previous 0.03%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 09, 2024

SELL
$33.72 - $47.33 $2,360 - $3,313
-70 Reduced 0.61%
11,400 $513,000
Q1 2024

Apr 15, 2024

SELL
$21.79 - $32.15 $5,447 - $8,037
-250 Reduced 2.13%
11,470 $332,000
Q3 2023

Oct 10, 2023

SELL
$16.68 - $23.66 $8,340 - $11,830
-500 Reduced 4.09%
11,720 $195,000
Q1 2023

Apr 12, 2023

SELL
$10.78 - $25.38 $323,400 - $761,400
-30,000 Reduced 71.06%
12,220 $281,000
Q2 2022

Jul 13, 2022

BUY
$7.06 - $25.52 $141,200 - $510,400
20,000 Added 90.01%
42,220 $334,000
Q3 2021

Oct 22, 2021

BUY
$12.95 - $49.69 $25,511 - $97,889
1,970 Added 9.73%
22,220 $394,000
Q2 2021

Aug 05, 2021

SELL
$25.57 - $44.88 $51,140 - $89,760
-2,000 Reduced 8.99%
20,250 $909,000
Q3 2020

Oct 21, 2020

SELL
$15.19 - $22.4 $15,949 - $23,520
-1,050 Reduced 4.51%
22,250 $435,000
Q2 2020

Aug 06, 2020

SELL
$6.19 - $18.84 $1,238 - $3,768
-200 Reduced 0.85%
23,300 $411,000
Q4 2018

Feb 14, 2019

SELL
$6.3 - $10.44 $22,050 - $36,540
-3,500 Reduced 12.96%
23,500 $158,000
Q3 2018

Oct 05, 2018

SELL
$6.82 - $11.26 $2,046 - $3,378
-300 Reduced 1.1%
27,000 $278,000
Q2 2018

Jul 16, 2018

SELL
$5.99 - $9.1 $116,206 - $176,540
-19,400 Reduced 41.54%
27,300 $183,000
Q4 2017

Jan 10, 2018

BUY
$14.47 - $20.8 $434,100 - $624,000
30,000 Added 179.64%
46,700 $971,000
Q3 2017

Oct 11, 2017

BUY
$10.61 - $17.98 $177,187 - $300,266
16,700
16,700 $295,000

Others Institutions Holding PTGX

About Protagonist Therapeutics, Inc


  • Ticker PTGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,084,100
  • Market Cap $2.28B
  • Description
  • Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...
More about PTGX
Track This Portfolio

Track Franklin Street Advisors Inc Portfolio

Follow Franklin Street Advisors Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Franklin Street Advisors Inc , based on Form 13F filings with the SEC.

News

Stay updated on Franklin Street Advisors Inc with notifications on news.